Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches - Top-Institutions - MDSpire

Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches

  • By

  • Wang, Euscia Y

  • XU, KEMAN

  • Shao, Ying

  • Lu, Yifan

  • Hung, Shih yu

  • Yuan, Bo

  • Xiang, Haiyan

  • Wang, Hong

  • Yang, MD, PhD, Professor Xiaofeng

  • July 2, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    UK Biobank
    UK Biobank

    London, England

    Key Differentiators

    • Cardiology

  • #2

    University of California Berkeley
    University of California Berkeley

    Berkeley, California

    Key Differentiators

    • Cardiology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology

  • #4

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Cardiology

  • #5

    Broad Institute of Harvard and MIT
    Broad Institute of Harvard and MIT

    Cambridge, Massachusetts

    Key Differentiators

    • Cardiology

Original Source(s)

Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches

  • by Wang, Euscia Y, XU, KEMAN, Shao, Ying, Lu, Yifan, Hung, Shih yu, Yuan, Bo, Xiang, Haiyan, Wang, Hong, Yang, MD, PhD, Professor Xiaofeng

  • July 2, 2026

Related Content

Potential association between IL-17A inhibition and blood pressure reduction in patients with axial spondyloarthritis

Psychological stress and diastolic blood pressure in cardiology outpatients: a multicenter cross-sectional study (from the ABC2X-2026 study)

Neighborhood Disinvestment and Racial Disparities in Early Hypertension Onset Among Women